1. Home
  2. IMCR vs VERA Comparison

IMCR vs VERA Comparison

Compare IMCR & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$35.36

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$45.16

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMCR
VERA
Founded
2008
2016
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
IMCR
VERA
Price
$35.36
$45.16
Analyst Decision
Buy
Strong Buy
Analyst Count
11
11
Target Price
$64.30
$76.60
AVG Volume (30 Days)
395.5K
1.1M
Earning Date
02-25-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$379,590,000.00
N/A
Revenue This Year
$32.42
N/A
Revenue Next Year
$11.17
N/A
P/E Ratio
N/A
N/A
Revenue Growth
28.11
N/A
52 Week Low
$23.15
$18.53
52 Week High
$40.72
$56.05

Technical Indicators

Market Signals
Indicator
IMCR
VERA
Relative Strength Index (RSI) 56.39 46.66
Support Level $32.00 $44.56
Resistance Level $34.71 $49.75
Average True Range (ATR) 1.56 2.46
MACD 0.18 -1.04
Stochastic Oscillator 92.76 10.71

Price Performance

Historical Comparison
IMCR
VERA

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Share on Social Networks: